254 related articles for article (PubMed ID: 25993188)
1. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
Weinstock M; McDermott DF
Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in immunotherapy for kidney cancer.
Ball MW; Allaf ME; Drake CG
Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
5. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
Gill D; Hahn AW; Sonpavde G; Agarwal N
Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy for Renal Cell Carcinoma].
Büchler T
Klin Onkol; 2015; 28 Suppl 4():4S64-8. PubMed ID: 26647891
[TBL] [Abstract][Full Text] [Related]
8. New immunotherapy in the treatment of advanced renal cancer.
Muto A; Gridelli C
Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164
[No Abstract] [Full Text] [Related]
9. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
10. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
13. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapy in metastatic renal cell carcinoma.
Cho YH; Kim MS; Chung HS; Hwang EC
Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030
[TBL] [Abstract][Full Text] [Related]
16. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
17. Emerging immunotherapies for renal cell carcinoma.
Escudier B
Ann Oncol; 2012 Sep; 23 Suppl 8():viii35-40. PubMed ID: 22918926
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
19. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
[TBL] [Abstract][Full Text] [Related]
20. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
